Smart mitochondrial-targeted cancer therapy: Subcellular distribution, selective TrxR2 inhibition accompany with...

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Mitochondrial redox homeostasis is a key target for cancer therapeutics, especially in drug-resistant cases with high antioxidant capacity.
• Developing targeted agents that disrupt this balance is crucial for effective cancer treatment.

Purpose of the Study:

• To synthesize and characterize a novel mitochondrial-targeted fluorescent probe, BODIPY-TPA (BTPA).
• To evaluate BTPA's potential as both a cancer-imaging probe and an anticancer agent targeting mitochondrial redox homeostasis.

Main Methods:

• Synthesis and characterization of BODIPY-TPA (BTPA).
• Confocal microscopy for subcellular localization studies.
• Cytotoxicity assays on BGC-823 cancer cells.
• Assessment of mitochondrial dysfunction, redox homeostasis, and apoptosis pathways.
• Inhibition studies involving TrxR2 and the PI3K/Akt signaling pathway.
• Reversal studies using N-acetylcysteine (NAC).

Main Results:

• BTPA demonstrated specific mitochondrial localization.
• BTPA exhibited selective anticancer activity against BGC-823 cells by inducing mitochondrial dysfunction.
• BTPA altered mitochondrial redox homeostasis, leading to mitochondrial reactive oxygen species (MtROS) accumulation.
• Inhibition of TrxR2 exacerbated MtROS accumulation and attenuated the PI3K/Akt pathway.
• BTPA induced intrinsic apoptosis via cytochrome C release and caspase-9 activation.
• N-acetylcysteine (NAC) reversed BTPA-induced apoptosis, confirming its ROS-dependent nature.

Conclusions:

• BTPA is a potent fluorescent probe for cancer imaging.
• BTPA effectively targets mitochondrial redox homeostasis, acting as an anticancer agent.
• The mechanism involves inducing oxidative stress, leading to apoptosis, making it a promising therapeutic strategy.